CINGULATE INC (CING) Stock News

USA - NASDAQ:CING - US17248W3034 - Common Stock

3.33 USD

-0.47 (-12.37%)

Last: 11/13/2025, 8:26:46 PM

3.33 USD

0 (0%)

After Hours: 11/13/2025, 8:26:46 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

CING Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: Cingulate Inc.

Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301

21 days ago - By: Cingulate Inc.

Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

a month ago - By: Stocktwits

News Image

Cingulate Stock Snaps 2-Day Losing Streak As Roth Hikes Target On ADHD Drug Review; Retail Bets On Buyout Potential

a month ago - By: Benzinga - Mentions: XRAY CCM SSKN SNOA ...

12 Health Care Stocks Moving In Tuesday's After-Market Session

2 months ago - By: Cingulate Inc.

Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment

a year ago - By: Benzinga

How Is The Market Feeling About Cingulate?

3 months ago - By: The Motley Fool

Cingulate Posts Wider Loss in Q2

3 months ago - By: Cingulate Inc.

Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

3 months ago - By: Cingulate Inc.

Cingulate Provides Management Team Update

3 months ago - By: Cingulate Inc.

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

4 months ago - By: Cingulate Inc.

Cingulate Appoints Nilay Patel as Chief Legal Officer to Support Growth ahead of New Drug Application

6 months ago - By: Life365

Life365 Appoints Healthcare Veteran Jay Roberts as Chief Development Officer

6 months ago - By: Stocktwits

Cingulate Retail Buzz Surges As ADHD Drug Shows Phase 3 Pediatric Efficacy

6 months ago - By: Stocktwits

Cingulate Retail Buzz Rises After FDA Greenlights Summer NDA Filing For ADHD Drug

6 months ago - By: Cingulate Inc.

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

7 months ago - By: Cingulate Inc.

Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)

7 months ago - By: Cingulate Inc.

Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301

8 months ago - By: Cingulate Inc.

Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved

8 months ago - By: Cingulate Inc.

Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On Track to File for FDA Approval Mid-2025

10 months ago - By: Cingulate Inc.

Final Study Completed for Cingulate’s Lead Asset CTx-1301

a year ago - By: Cingulate Inc.

Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

a year ago - By: Cingulate Inc.

Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

a year ago - By: Cingulate Inc.

Cingulate’s Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

a year ago - By: Cingulate Inc.

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

a year ago - By: Cingulate Inc.

Cingulate to Participate in Benzinga All Live Access Event

a year ago - By: Cingulate Inc.

Cingulate Announces Adjournment of Special Meeting